A novel antithrombin domain dictates the journey's end of a proteinase
- PMID: 28986431
- PMCID: PMC5633113
- DOI: 10.1074/jbc.H117.787325
A novel antithrombin domain dictates the journey's end of a proteinase
Abstract
Antithrombin (AT) is an anticoagulant serpin that irreversibly inactivates the clotting proteinases factor Xa and thrombin by forming covalent complexes with them. Mutations in its critical domains, such as those that impair the conformational rearrangement required for proteinase inactivation, increase the risk of venous thrombosis. Águila et al. characterize for the first time the destabilizing effects of mutations in the region of AT that makes contact with the proteinase in the final acyl-enzyme complex. Their work adds new insight into the unique structural intricacies of the inhibitory mechanism.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.
Conflict of interest statement
The author declares that she has no conflicts of interest with the contents of this article
Figures
Comment on
-
Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities.J Biol Chem. 2017 Oct 6;292(40):16513-16520. doi: 10.1074/jbc.M117.787325. Epub 2017 Jul 25. J Biol Chem. 2017. PMID: 28743742 Free PMC article.
References
-
- Olson S. T., and Gettins P. G. (2011) Regulation of proteases by protein inhibitors of the serpin superfamily. Prog. Mol. Biol. Transl. Sci. 99, 185–240 - PubMed
-
- Dementiev A., Dobó J., and Gettins P. G. (2006) Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of alpha1-proteinase inhibitor with porcine pancreatic elastase. J. Biol. Chem. 281, 3452–3457 - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
